Rapid Health Technology Assessment of Azacitidine in the Treatment of Myelodysplastic Syndrome

SHEN Liucen; HUANG Lei; ZHANG Chunyan; SHEN Kai

doi:10.14009/j.issn.1672-2124.2022.11.022

您当前的位置：

首页 >

文章列表页 >

Rapid Health Technology Assessment of Azacitidine in the Treatment of Myelodysplastic Syndrome

更新时间：2023-04-16

- Rapid Health Technology Assessment of Azacitidine in the Treatment of Myelodysplastic Syndrome
- Issue 11, Pages: 1380-1382(2022)
- 作者机构：
  
  1. 南通市海门区人民医院药剂科
  2. 南通大学附属医院药学部
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.11.022
  CLC： R551.3
- Published：2022，
扫描看全文
SHEN Liucen, HUANG Lei, ZHANG Chunyan, et al. Rapid Health Technology Assessment of Azacitidine in the Treatment of Myelodysplastic Syndrome. [J]. (11):1380-1382(2022)
DOI：

SHEN Liucen, HUANG Lei, ZHANG Chunyan, et al. Rapid Health Technology Assessment of Azacitidine in the Treatment of Myelodysplastic Syndrome. [J]. (11):1380-1382(2022) DOI： 10.14009/j.issn.1672-2124.2022.11.022.

摘要

目的：基于快速卫生技术评估方法，评价阿扎胞苷治疗骨髓增生异常综合征的有效性、安全性和经济性，高效、快捷地为临床药物选择和决策者提供循证依据。方法：系统检索中国知网、万方数据库、PubMed和the Cochrane Library等数据库，纳入阿扎胞苷与对照组（地西他滨或其他治疗手段）治疗骨髓增生异常综合征的系统评价/Meta分析、药物经济学研究等文献，由2名评价者根据纳入与排除标准独立筛选文献、提取资料和汇总数据后，最终采用定性描述的方法对结果进行定性分析。结果：共纳入7篇系统评价/Meta分析和2篇药物经济学研究文献。现有证据显示，阿扎胞苷治疗骨髓增生异常综合征在有效性方面较对照药物有一定的优势，且不增加患者的血液毒性。阿扎胞苷和地西他滨在我国均具有较好的经济性。结论：与支持治疗相比，去甲基化药物应优先被推荐用于治疗骨髓增生异常综合征患者；而与地西他滨比较，阿扎胞苷更具有有效性。

Abstract

OBJECTIVE: To evaluate the efficacy

safety and economy of azacitidine in the treatment of myelodysplastic syndrome based on rapid health technology assessment

so as to provide evidence-based evidence for drug selection and decision-makers conveniently. METHODS: Systematic review/Meta-analysis and pharmacoeconomic studies on azacitidine and control group（decitabine or other treatments） in the treatment of myelodysplastic syndrome were systematically retrieved from CNKI

Wanfang Data

PubMed

the Cochrane Library and other databases. Literature screening

data extraction and summary were performed according to the inclusion and exclusion criteria by two evaluators independently

so that the conclusion was qualitatively analyzed through qualitative description. RESULTS: Totally seven systematic review/Meta-analysis and two pharmacoeconomic studies were included. Existing evidence indicated that compared with the control group

azacitidine had a certain advantage of efficacy in the treatment of myelodysplastic syndrome without increasing patients’ hematotoxicity. Both azacitidine and decitabine had good economy in China. CONCLUSIONS: Compared with supportive treatment

the demethylation agents should be recommended for the treatment of myelodysplastic syndrome. Moreover

azacitidine is more effective than decitabine.

关键词

卫生技术评估阿扎胞苷骨髓增生异常综合征

Keywords

Health technology assessmentAzacitidineMyelodysplastic syndrome

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Comprehensive Clinical Evaluation of Sodium Aescinate for Injection

Rapid Health Technology Assessment of Ozagrelay Sodium Injection for Acute Cerebral Infarction

Process of Clinical Molecular of Azacitidine and Decitabine in the Treatment of Hematological Tumors

Related Author

赵紫楠

赵飞

李婷

张亚同

金鹏飞

LI Chao

YANG Zixian

LUO Taimin

Related Institution

Beijing Hospital

Dept.of Pharmacy,Beijing Hospital/National Center of Gerontology/Institute of Geriatric Medicine,Chinese Academy of Medical Science

Clinical Trial Center,Beijing Hospital/National Center of Gerontology

Dept. of Pharmacy, China-Japan Friendship Hospital

⁰